ACXION AP PHENTERMINE 30MG 30TABS

Phentermine hydrochloride is an anorectic with a sympathomimetic effect on the central nervous system, reducing appetite by stimulating the release of norepinephrine in the hypothalamus. After oral administration, it is easily absorbed from the digestive tract, 17.5% is bound to plasma proteins, and its half-life is approximately 20 hours. Its metabolization is extensive through a complex biotransformation pathway that involves oxidative deamination and reduction of many of its biologically active metabolites that can participate in therapeutic action. The excretion of phentermine is mainly through the kidneys, eliminating 62-85% of the drug without change.

Obesity is a chronic disease and requires chronic therapy. Hypertension, dyslipidemia, diabetes, and cardiovascular diseases are the leading causes of mortality in the modern world, all closely linked to obesity. Obese patients should always be treated through lifestyle interventions, however, despite these types of interventions, the results remain modest. On the other hand, but in the same sense, pharmacotherapy is a second step in the treatment of obesity, approved when weight loss goals were not achieved through lifestyle intervention.

To promote long-term weight maintenance, the use of weight loss medications is suggested to reduce comorbidities and improve adherence to behavioral changes, which can improve the physical functionality of patients and allow them to develop greater physical activity. When patients respond effectively to weight loss drugs (≥ 5% body weight loss in three months), it is recommended to continue the drug.

The use of phentermine has been studied for up to 36 weeks (2-36) with doses of 15-30 mg / day, showing additional weight loss. Its use for 36 weeks with 30 mg / day continuously or intermittently (4 weeks with treatment and 4 weeks without treatment) also showed a significant decrease in weight, with few adverse effects (8% of patients). The duration of treatment with phentermine does not influence adverse effects. The advantage of the prolonged release formulation should be considered in avoiding high concentrations that are associated with dependency phenomena. It is advisable to evaluate the efficacy and safety at least monthly during the first three months and every three months thereafter.

ACXION® AP should not be co-administered or for 14 days after the administration of monoamine oxidase inhibitors, as hypertensive crisis may result, the abuse of Phentermine as a means to overcome drowsiness or alertness should not be encouraged; Furthermore, its use is not recommended in people with anorexia, insomnia, asthenia, psychotic personality, pregnancy and lactation.